Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections
Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections
Sponsor: Materia Medica Holding
Listed as NCT03707912, this PHASE4 trial focuses on Acute Respiratory Viral Infections and remains completed. Sponsored by Materia Medica Holding, it has been updated 10 times since 2018, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Apr 2020 — Oct 2020 [monthly]
Completed PHASE4
-
Sep 2019 — Apr 2020 [monthly]
Completed PHASE4
-
Jun 2019 — Sep 2019 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE4
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE4
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Materia Medica Holding
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barnaul, Russia , Chelyabinsk, Russia , Kazan', Russia , Krasnogorsk, Russia , Moscow, Russia , Podolsk, Russia , Reutov, Russia , Saint Petersburg, Russia , Saratov, Russia , Smolensk, Russia and 1 more location